Drugs / MITI-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07238790 | Dec 2025 → Dec 2028 expected | diarrheal disease, irritable bowel syndrome | Stanford University | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MITI-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07238790 ↗ |
| Action | Restore | “restore the altered microbial metabolic process” NCT07238790 ↗ |
| Modality | Other / unclassified | “MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains” NCT07238790 ↗ |
| Route | Other | “one dose of MITI-001 will be administered endoscopically to the duodenum (via esophagogastroduodenoscopy)” NCT07238790 ↗ |